Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY: EBS )

8.300 +0.150 (+1.84%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst
Although blue chips provide greater predictability, these top small-cap stocks to buy may drive intense growth for speculators. 
Via InvestorPlace
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
From Emergent BioSolutions
Via GlobeNewswire
FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility
Via Benzinga
Merck Partner Joins Forces With Emergent Bio To Increase Access To Ebola Treatment
Via Benzinga
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects. EBS-LASV is a recombinant VSV-vectored Lassa... 
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
3 Top Monkeypox Stocks to Buy Right Now
With cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now. 
Via InvestorPlace
Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch
The only FDA-approved monkeypox vaccine from Bavarian Nordic A/S (OTC: BVNY) is in short supply. 
Via Benzinga
Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test
Via Benzinga
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments. 
Via Benzinga
WeTrade Shares Soar On Collaboration Over Exclusive COVID-19 Omicron Disinfectant
Via Benzinga
A Biopharma Working On Malaria, Norovirus Vaccines Threw It's Hat In The Monkeypox Ring
Blue Water Vaccines Inc (NASDAQ: BWV)  
Via Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
The Only Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand
Bavarian Nordic A/S (OTC: BVNKF), the only company with an approved vaccine for monkeypox, said it’s no longer sure it can meet demand as cases continue to rise worldwide, 
Via Benzinga
WeTrade's Monkeypox Testing Kits May Go Global. Why A New Agreement Is Sending Shares Soaring Double Digits?
Via Benzinga
Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus
Via Benzinga
Avis Budget, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
  FAT Brands Inc. (NASDAQ: FATBB) fell 30% to $10.50. The company recently posted a Q2 net loss of $8.2 million or $0.50 per share. 
Via Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks. 
Via Benzinga
Why Applied DNA Sciences Is Trading Higher By 166%, Here Are 75 Stocks Moving In Tuesday's Mid-Day Session
Gainers AMTD IDEA Group (NYSE: AMTD) shares jumped 284% to $8.00 after jumping 18% on Monday. The company owns 90%+ of AMTD Digital. 
Via Benzinga
Recap: Emergent BioSolutions Q2 Earnings
Emergent BioSolutions (NYSE:EBS) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
Monkeypox stocks are rallying today amid worries about a shortage of vaccines for the illness in the United States. 
Via InvestorPlace
Earnings Outlook For Emergent BioSolutions
Emergent BioSolutions (NYSE:EBS) is set to give its latest quarterly earnings report on Monday, 2022-08-01. Here's what investors need to know before the announcement. Analysts estimate that Emergent... 
Via Benzinga
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency
Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. 
Via InvestorPlace
WWE, Infrastructure and Energy Alternatives And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
  Infrastructure and Energy Alternatives, Inc. (NASDAQ: IEA) shares rose 26% to $13.14 in pre-market trading. MasTec announced plans to acquire Infrastructure and Energy Alternatives for $14 per share... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 1, 2022
Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter. 
Via Benzinga
Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
Pharmaceutical companies that make vaccines against monkeypox are getting attention as demand for treatments against the virus grow. 
Via InvestorPlace
White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know
Via Benzinga
U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review
The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE: EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909. The regulatory... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.